Gene Logic Inc.
Drug discovery and development solutions
Gene Logic consists of three business units: Genomics and Toxicogenomics, Nonclinical Services, and the Drug Repositioning and Selection™ programme.
The company has an extensive portfolio of gene reference and clinical database systems, software, toxicity consulting services, and gene expression and genotyping microarray data generation outsourcing services. In addition, the company also provides state-of-the-art contract research servicesextending from proof-of-concept through clinical development support.
Charles L. Dimmler, III (Chief Executive Officer and President)
Philip L. Rohrer, Jr (Chief Financial Officer)
610 Professional Drive
Gaithersburg, MD 20879
USA
Phone: +1-301-987-1700
Toll Free: 800.GENELOGIC (800.436.3564)
Fax: +1-301-987-1701
Related patents
- Computer methods and systems for displaying information relating to gene expression data
- Methods and systems for efficient comparison, identification, processing, and importing of gene expression data
- Method for identifying variations in polynucleotide sequences
- Method and system for computationally identifying clusters with a set of sequences
- Coding sequences of the human BRCA1 gene
Related news
- Gene Logic Inc. Completes Sale of Genomics Assets to Ocimum Biosolutions
- Gene Logic Promotes Bethany Mancilla to Senior Vice President of Business Development
- Gene Logic Drug Repositioning Program Discovery Results in Filing of New Therapeutic Use Patent by Pfizer
- Gene Logic Selects New Company Name: Ore Pharmaceuticals Inc.
- Gene Logic Identifies Gene Expression Patterns Associated with Multiple Sclerosis in Blood Cells
- Gene Logic Agrees to Sell Genomics Assets
- Gene Logic and Solvay Pharmaceuticals Enter Agreement to Discover New Development Paths for Multiple Clinical Drug Candidates
- Gene Logic Recruits Pharmaceutical Executive as Senior Vice President of Clinical Development
- Gene Logic Drug Candidate Shows Positive In Vivo Test Results
- Gene Logic and Abbott Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
- Gene Logic Promotes Dr. Thomas Barnes to Lead Drug Repositioning Discovery Efforts
- Gene Logic Board Elects Two New Directors
- Gene Logic Names New CEO
- Gene Logic to Announce Fourth Quarter and Full Year 2006 Financial Results on February 23, 2007
- Gene Logic Completes Sale of Preclinical Division
- Gene Logic Enters into Agreement with Gene Logic Enters into Agreement with Lilly to Discover New Development Paths for Multiple Clinical Drug Candidates
- Gene Logic Provides Update on Business Review
- Gene Logic Provides the FDA with Access to Toxicogenomics Data and Analysis Systems for Reviewing Voluntary Genomic Data Submissions
- Gene Logic Restructures Genomics Division
- Gene Logic to Announce Second Quarter 2006 Financial Results on August 4, 2006
- Gene Logic to Realize Lower-Than-Expected Revenue for Its Genomics Division; Financial Guidance Withdrawn
- Gene Logic and Organon Enter Collaboration to Find New Therapeutic Applications for Clinical Drug Candidates
- Gene Logic Reports First Quarter 2006 Financial Results; Outlook Remains Strong, Guidance Confirmed; Drug Repositioning Partnerships Expanded
- Gene Logic to Announce First Quarter 2006 Financial Results on April 21, 2006
- Gene Logic Recruits Industry Veteran to Lead Preclinical Business Sales and Marketing; Mark T. Crane, Vice President of Business Development and Marketing, Brings Expertise from Career with Top Pharmaceutical Service Providers
- Gene Logic Reports Fourth Quarter and Full Year 2005 Financial Results; Record Quarterly and Annual Revenue
- Gene Logic Announces Enhanced Software for Drug Target Discovery and Compound Safety Assessment